FBIO Earnings

FBIO reported its earnings on 2025-11-13, showcasing a revenue of 0.00 against an estimate of 24.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.43 by 0% . The stock experienced a 5.22% price change on the earnings day and a 4.42% change over the next five days, reflecting market reactions to the results.

Following FBIO's earnings announcement on 2025-11-13, the stock price moved by 5.22% on the day of the release. Over the subsequent five days, it saw a 4.42% change. Historically, FBIO's stock price tends to shift by an average of -0.19% in the 10 days leading up to earnings and +0.35% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate FBIO’s annual revenue to reach 21.00M, while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between FBIO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, FBIO's stock price typically moves by -0.19% in the 10 days before its earnings and +0.35% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -1.00 and revenue of 21.00M.

The earnings call reveals positive indicators: improved EBITDA, increased cash reserves, and strong EMROSI growth. The Q&A highlights optimistic future prospects with expanding prescriber base and increasing reimbursements. Despite some uncertainties, such as lack of specific guidance and retention rates, the overall sentiment is positive, driven by EMROSI's successful launch and expected revenue growth. The lack of market cap information limits precise prediction, but given the strong product performance and financial health, a positive stock price movement of 2% to 8% is anticipated.